Abstract 17312: Amyloid-β (1-40) and the Risk of Death from Cardiovascular Causes in Patients with Coronary Heart Disease

Circulation ◽  
2014 ◽  
Vol 130 (suppl_2) ◽  
Author(s):  
Kimon Stamatelopoulos ◽  
Dirk Sibbing ◽  
Loukianos S Rallidis ◽  
Georgios Georgiopoulos ◽  
Dimitrios Stakos ◽  
...  
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Arterial Stiffness ◽  
Healthy Subjects ◽  
Subclinical Atherosclerosis ◽  
Amyloid Β ◽  
High Sensitivity ◽  
Left Ventricular Ejection ◽  
Clinical Value ◽  
Prospective Cohorts

Introduction: Investigation of the clinical value of biologic pathways that are involved in pathogenesis of atherosclerotic disease is essential for identification of novel therapeutic targets and improvement of cardiovascular risk stratification. Hypothesis: To determine the clinical value of amyloid-β 1-40 (Aβ40) measurement in predicting cardiovascular (CV) mortality in patients with coronary heart disease (CHD) and arterial stiffness progression in young healthy subjects. Methods: Aβ40 was retrospectively measured in blood samples collected from three independent prospective cohorts and two case-control cohorts (total n=1464). Major adverse CV events (MACE) were assessed in the two prospective cohorts (n=877) followed for a median of 4.4 years. Arterial stiffness was evaluated at baseline and after a 5-year follow-up period (n=107) in young healthy subjects. The primary endpoint was the predictive value of Aβ40 for CV mortality and outcomes in patients with CHD. Further, the associations of Aβ40 levels with arterial stiffness progression, incident subclinical atherosclerosis and incident CHD were addressed. Results: In Cox proportional-hazards models adjusted for age, gender, glomerular filtration rate, left ventricular ejection fraction, high-sensitivity C-reactive protein and high-sensitivity troponin-T, Aβ40 was an independent predictor of CV death and MACE in patients with CHD (P<0.05 for all). After multivariate adjustment, Aβ40 levels conferred a substantial enhancement of net reclassification index (continuous NRI value and 95% confidence interval: 36.7%, 12.5-60.7, P=0.001) and integrated discrimination improvement (IDI value±SE: 1.92±0.62, P<0.001) of individuals at risk in the total combined CHD cohort over the best predictive model. Further cohort-based analysis revealed that Aβ40 levels were significantly and independently associated with arterial stiffness progression, incident subclinical atherosclerosis and incident CHD. Conclusions: Measuring blood levels of Aβ40 identifies patients at high risk for cardiovascular death.

Assessment of the Type D personality distress in coronary heart disease patients and healthy subjects in Spain

2019 ◽  
Vol 142 ◽  
pp. 301-309
Author(s):  
Anton Aluja ◽  
Olga Malas ◽  
Ignacio Lucas ◽  
Fernando Worner ◽  
Ramon Bascompte
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Healthy Subjects ◽  
Type D Personality ◽  
Type D

Non-Fasting Changes of Hs-CRP Level in Chinese Patients With Coronary Heart Disease After A Daily Meal

2021 ◽  
Author(s):  
Ling Liu ◽  
Qiu-Zhen Lin ◽  
Xue-Yan Zang ◽  
Yan Fu ◽  
Xingyu Wen ◽  
...  
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
High Sensitivity ◽  
Chinese Patients ◽  
Inflammatory Factor ◽  
Fasting State ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Hs Crp ◽  
Atherosclerotic Cardiovascular Diseases

Abstract High-sensitivity C-reactive protein (hs-CRP) is a key inflammatory factor in atherosclerotic cardiovascular diseases. In Chinese patients with coronary heart disease (CHD), the changes in hs-CRP levels after a daily meal and the effect of statins on those were never explored. A total of 300 inpatients with CHD were included. Hs-CRP levels were measured in fasting and non-fasting state at 2 hour (h) and 4h after a daily breakfast. Group with fasting hs-CRP ≤ 3mg/L had significantly higher percentage of patients with statins using ≥ 1 month (m) than that with fasting hs-CRP > 3mg/L (51.4% vs. 23.9%, P < 0.05). Hs-CRP levels were significantly higher in non-fasting state (P < 0.05). Interestingly, the hs-CRP didn’t elevate significantly in inpatients with statins using ≥ 1m in hs-CRP > 3mg/L group, but it elevated significantly after meal in inpatients without and with statins using < 1m (P < 0.05). About 32% of patients with non-fasting hs-CRP > 3mg/L came from those with fasting hs-CRP ≤ 3mg/L. In conclusion, hs-CRP levels increased significantly in CHD patients after a daily meal. When fasting hs-CRP > 3mg/L but not ≤ 3mg/L, statins work partly in reducing hs-CRP elevation in non-fasting state.

scholarly journals Analysis on the Expression and Prognostic Value of LncRNA FAF in Patients with Coronary Heart Disease

2020 ◽  
Vol 2020 ◽  
pp. 1-8
Author(s):  
Hai Xu ◽  
Xiwen Zhang ◽  
Kun Yu ◽  
Gang Zhang ◽  
Yafei Shi ◽  
...  
Keyword(s):  
Risk Factors ◽  
Coronary Heart Disease ◽  
Heart Disease ◽  
Poor Prognosis ◽  
Prognostic Value ◽  
High Sensitivity ◽  
Control Group ◽  
Coronary Lesion ◽  
Tnf Α ◽  
Factor Α

Objective. To investigate the expression and prognostic value of LncRNA FAF in patients with coronary heart disease. Patients and Methods. 97 patients with coronary heart disease who came to our hospital were selected as the research group (RG), and 97 healthy people who came to our hospital for physical examination during the same period were selected as the control group (CG). The serum LncRNA FAF, plasma homocysteine (HCY), lipoprotein A (Lp-a), serum tumor necrosis factor α (TNF-α), and high-sensitivity C-reactive protein (hsCRP) in the two groups of patients were detected, and their correlations were analyzed. Then, the predictive value and risk factors of FAF for poor prognosis of patients with coronary heart disease were analyzed. Results. The expression of LncRNA FAF in the serum of patients in the RG was significantly lower than that in the CG, and the expressions of HCY, Lp-a, TNF-α, and hsCRP were significantly higher than those in the CG (p <0.05). The AUC of FAF in the diagnosis of coronary heart disease was more than 0.9. FAF was negatively correlated with the coronary lesion vessels, HCY, Lp-a, TNF-α, and hsCRP expressions in patients with coronary heart disease ( p < 0.05 ). The ROC of FAF for predicting poor prognosis in patients with coronary heart disease was greater than 0.9. Low expression of FAF; high expressions of HCY, Lp-a, and hsCRP; and increase of coronary lesion vessels were independent risk factors for poor prognosis in patients with coronary heart disease. Conclusions. LncRNA FAF was lowly expressed in the serum of patients with coronary heart disease, and it was of high value in the diagnosis and prediction of poor prognosis of coronary heart disease. It was also an independent risk factor for poor prognosis of patients with coronary heart disease and may be a potential target for diagnosis and treatment of coronary heart disease.

Sign in / Sign up

Export Citation Format

Share Document